# A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

> **NCT01850602** · PHASE3 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 213 (actual)

## Conditions studied

- Hemodialysis
- Hyperphosphatemia

## Interventions

- **DRUG:** PA21
- **DRUG:** Sevelamer hydrochloride

## Key facts

- **NCT ID:** NCT01850602
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-23
- **Primary completion:** 2013-12
- **Final completion:** 2013-12-10
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01850602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01850602, "A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01850602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*